Combined cocaine and HIV vaccine

可卡因和艾滋病毒联合疫苗

基本信息

项目摘要

DESCRIPTION (provided by applicant): Targeting the high-risk groups that are responsible for most of the transmission of HIV is a major challenge in biomedical research on HIV/AIDS. Substance abusers are one of the key high-risk groups, and, specifically, inner city crack cocaine users are three times more likely than non-users to be infected with HIV. We hypothesize that a vaccine that raises protective antibodies simultaneously to both cocaine and HIV could be a high-impact intervention in these populations. Such a vaccine may be feasible, because the first epitopes shown to protect against the acquisition of HIV have been identified by a consortium of scientists analyzing the results of the recent RV144 trial (Haynes et. al. NEJM 2012). Their analysis showed that the protective epitopes are located in the second variable loop (V2 loop) of the surface envelope glycoprotein of the HIV virus. Over the past few years, my laboratory has developed a technology platform for eliciting specific antibody responses from variable loop epitopes, including the V2 loop. Based on these data, we believe that we can develop an immunogen capable of eliciting HIV-protective antibodies. By coincidence, the same scaffold protein used to elicit these antibodies in our work has been used successfully as a cocaine vaccine in a clinical trial. Thus, an advanced starting point is present to develop a combined cocaine and HIV vaccine. Such a vaccine would be a precedent-setting molecular intervention at the intersection of HIV/AIDS and substance abuse, and may have a transformative effect on both fields. In the adaptation of our HIV vaccine immunogen design work to the problem of drug abuse, this proposed project represents a significant departure from the ideas and approaches that are currently being pursued in the our lab, so this proposal is ideal for the NIDA Avante-Garde Award Program for HIV/AIDS Research.
描述(由申请人提供):针对艾滋病毒传播的高危人群是艾滋病毒/艾滋病生物医学研究的主要挑战。药物滥用者是关键的高危群体之一,具体而言,市中心快克可卡因使用者感染艾滋病毒的可能性是非吸毒者的三倍。我们假设,一种同时提高对可卡因和艾滋病毒的保护性抗体的疫苗可能是对这些人群的高影响干预。这种疫苗可能是可行的,因为一个科学家联盟在分析最近的RV144试验结果后,已经确定了第一批显示可防止获得艾滋病毒的抗原表位(Haynes等人,NEJM 2012)。他们的分析表明,保护性表位位于HIV病毒表面包膜糖蛋白的第二个可变环(V2环)。在过去的几年中,我的实验室开发了一种技术平台,用于从包括V2环在内的可变环表位中激发特异性抗体反应。基于这些数据,我们相信我们可以开发出一种能够激发hiv保护性抗体的免疫原。巧合的是,在我们的研究中用于引发这些抗体的支架蛋白在临床试验中被成功地用作可卡因疫苗。因此,为研制可卡因和艾滋病毒联合疫苗提供了一个先进的起点。这种疫苗将是在艾滋病毒/艾滋病和药物滥用交叉领域开创先例的分子干预,并可能对这两个领域产生变革性影响。在将我们的HIV疫苗免疫原设计工作应用于药物滥用问题的过程中,这个提议的项目与我们实验室目前所追求的想法和方法有很大的不同,因此这个提议是NIDA HIV/AIDS研究先锋奖项目的理想选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIMOTHY J CARDOZO其他文献

TIMOTHY J CARDOZO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIMOTHY J CARDOZO', 18)}}的其他基金

Discovery of novel openers of the understudied human drug target Kir6.1
发现正在研究的人类药物靶标 Kir6.1 的新开启子
  • 批准号:
    10580933
  • 财政年份:
    2022
  • 资助金额:
    $ 6.53万
  • 项目类别:
ADE-minimized COVID-19 vaccine via epitope focusing and anti-inflammatory innate immunity
通过表位聚焦和抗炎先天免疫实现 ADE 最小化的 COVID-19 疫苗
  • 批准号:
    10161068
  • 财政年份:
    2020
  • 资助金额:
    $ 6.53万
  • 项目类别:
Epitope optimization for heterologous prime-boost HIV vaccines
异源初免-加强 HIV 疫苗的表位优化
  • 批准号:
    9138212
  • 财政年份:
    2016
  • 资助金额:
    $ 6.53万
  • 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
  • 批准号:
    8698061
  • 财政年份:
    2014
  • 资助金额:
    $ 6.53万
  • 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
  • 批准号:
    9263411
  • 财政年份:
    2014
  • 资助金额:
    $ 6.53万
  • 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
  • 批准号:
    9379050
  • 财政年份:
    2014
  • 资助金额:
    $ 6.53万
  • 项目类别:
Structure Based Characterization of gp120 Non-V3 Variable Loop Epitopes
gp120 非 V3 可变环表位的基于结构的表征
  • 批准号:
    8733248
  • 财政年份:
    2014
  • 资助金额:
    $ 6.53万
  • 项目类别:
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
稳定核 p27kip1 作为子宫内膜癌的治疗靶点
  • 批准号:
    9094005
  • 财政年份:
    2014
  • 资助金额:
    $ 6.53万
  • 项目类别:
Combined cocaine and HIV vaccine
可卡因和艾滋病毒联合疫苗
  • 批准号:
    8606078
  • 财政年份:
    2013
  • 资助金额:
    $ 6.53万
  • 项目类别:
Combined cocaine and HIV vaccine
可卡因和艾滋病毒联合疫苗
  • 批准号:
    8727501
  • 财政年份:
    2013
  • 资助金额:
    $ 6.53万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.53万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了